Posted 30th January 2019 by Jane Williams
In just two years’ time, the digital PCR and qPCR market is set to be worth an estimated $4.94 billion. Dedicated sessions at the 4BIO Summit covered topics such as gene expression analysis, liquid biopsies and high-throughput screening. We have made the following presentation slides from Hendrik Emons, Naomi Park & Mike Makrigiorgos available.
Posted 23rd November 2018 by Jane Williams
One of the most amazing aspects surrounding us is life itself – not just humans, but the environment: trees, flowers, insects, animals and even bacteria. They all share one central molecule which is crucial for their existence.
Posted 2nd November 2018 by Jane Williams
Triple-d PCR enhances digital PCR sensitivity and precision for liquid biopsies
Digital-droplet PCR (ddPCR) has been implemented in diverse fields such as cancer biomarkers, viral load detection, prenatal screening, organ donor rejection, or library assessment for next generation sequencing. Detection of emerging resistance or minimal residual disease via ddPCR in liquid biopsies is also growing rapidly.
Posted 31st October 2018 by Jane Williams
One of the most powerful applications of genome editing is the introduction of nucleotide substitutions in specific genomic sites. This can be used to mimic single-nucleotide polymorphisms (SNPs) or to generate stop codons that yield precise gene knockouts. However, screening hundreds of clones for a single edited nucleotide remains a challenge, especially in the absence of a corresponding phenotype.
Posted 4th June 2018 by Jane Williams
qPCR and dPCR are mature analytical methods for quantifying selected genetic materials in a sample. Both utilise the PCR method to amplify amounts as small as a single molecular fragment (template) to levels where they can be easily detected, usually by fluorescence techniques.
Posted 30th May 2018 by Jane Williams
The global qPCR & dPCR instrumentation market is growing and is expected to reach 1631.09 million USD by the end of 2025.
Posted 14th May 2018 by Jane Williams
Our understanding of the aberrant biological pathways (oncogenic pathways) that are involved in the formation and progression of cancers has increased with huge leaps in the last decades of cancer research. The ever-increasing knowledge was and still is accompanied by the development of increasing numbers of precision drugs, tailored to neutralize these aberrations.